ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in ...

ATH434 is designed to reduce α-synuclein aggregation and oxidative stress by binding to and redistributing excess loosely bound iron in the brain.

The human brain can learn through ... after we have encountered them multiple times. This learned suppression is an important component of the human visual system, which is otherwise strongly ...

it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the ...

"The dosing of our first patient in the Phase 2 clinical trial of YA-101 for Multiple System Atrophy represents a big step forward as we strive to bring a much-needed treatment option to ...

Billions of nerve cells that make up the gray matter in our brain allow us to perform these ... Ultrastructural Axon–Myelin Unit Alterations in Multiple Sclerosis Correlate with Inflammation ...

[15,16] Brain MRI was performed in all subjects to rule out structural abnormalities that can mimic MSA. Additional exclusion criteria included the presence of dementia and volume depletion.

For this reason, and given the previously shown link between stress-system hyperactivity and regional gray matter (GM) atrophy in PwMS (9), we ... To constrain all MRI group analyses to brain areas ...

Objective: Brain atrophy is an established biomarker for dementia, yet spinal cord involvement has not been investigated to date. As the spinal cord is relaying sensorimotor control signals from the ...